Compare BTCT & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTCT | BIVI |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | Singapore | United States |
| Employees | 26 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.3M |
| IPO Year | N/A | 2013 |
| Metric | BTCT | BIVI |
|---|---|---|
| Price | $0.52 | $1.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 319.0K | 196.6K |
| Earning Date | 05-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $283.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.06 |
| 52 Week High | $3.12 | $6.01 |
| Indicator | BTCT | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 25.18 | 49.25 |
| Support Level | N/A | $1.20 |
| Resistance Level | $1.21 | $1.67 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 1.12 | 56.14 |
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.